Compare HRTG & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | CTMX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 670.9M | 642.2M |
| IPO Year | 2014 | 2015 |
| Metric | HRTG | CTMX |
|---|---|---|
| Price | $26.50 | $3.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $33.50 | $12.10 |
| AVG Volume (30 Days) | 355.6K | ★ 5.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $847,330,000.00 | $76,201,000.00 |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $6.74 | $7.61 |
| P/E Ratio | $23.34 | ★ $22.58 |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $16.83 | $1.72 |
| 52 Week High | $31.98 | $8.21 |
| Indicator | HRTG | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 51.63 |
| Support Level | $25.28 | $3.40 |
| Resistance Level | $27.73 | $3.90 |
| Average True Range (ATR) | 1.04 | 0.24 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 56.37 | 48.10 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.